Skip to content
2000
Volume 18, Issue 20
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The conventional way of characterizing a disease consists of correlating clinical symptoms with pathological findings. Although this approach for many years has assisted clinicians in establishing syndromic patterns for pathophenotypes, it has major limitations as it does not consider preclinical disease states and is unable to individualize medicine. Moreover, the complexity of disease biology is the major challenge in the development of effective and safe medicines. Therefore, the process of drug development must consider biological responses in both pathological and physiological conditions. Consequently, a quantitative and holistic systems biology approach could aid in understanding complex biological systems by providing an exceptional platform to integrate diverse data types with molecular as well as pathway information, leading to development of predictive models for complex diseases. Furthermore, an increase in knowledgebase of proteins, genes, metabolites from high-throughput experimental data accelerates hypothesis generation and testing in disease models. The systems biology approach also assists in predicting drug effects, repurposing of existing drugs, identifying new targets, facilitating development of personalized medicine and improving decision making and success rate of new drugs in clinical trials.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026618666181025113226
2018-08-01
2025-09-18
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026618666181025113226
Loading

  • Article Type:
    Review Article
Keyword(s): Biomarkers; CVD; Drug combinations; Drug repurposing; Dynamical models; Network models
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test